Abstract: The present invention relates to a compound represented by general formula (I) or a stereoisomer, a tautomer, a deuterated substance, a solvate, a prodrug, a metabolite and a pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, and a use of the compound in METTL3-related diseases such as cancer.

Abstract: A supporting assembly adapted for a rack is provided and includes a supporting bracket, a plurality of slide rails, a plurality of movable rails and a plurality of supporting rails. The supporting bracket is configured to be mounted on the rack and includes a first predetermined end portion and a second predetermined end portion. The plurality of slide rails are configured to be detachably mounted on the supporting bracket. The plurality of supporting rails are movably mounted on the plurality of movable rails movably mounted on the plurality of slide rails, respectively. Each of the plurality of slide rails includes a first end portion, a second end portion, and a middle portion located between the first end portion and the second end portion. The first predetermined end portion of the supporting bracket protrudes from the first end portion of each of the plurality of slide rails along a longitudinal direction.

Abstract: The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, and an intermediate thereof, and use thereof in IRAK4-related diseases such as an autoimmune disease, an inflammatory disease or cancer.

Abstract: The present invention relates generally in part to BeO-based compounds that are capable of storing at least part of the energy of incident ionizing radiation and releasing at least part of the stored energy upon optical stimulation and heating. BeO-based compounds dosimetry was also developed in instrumentation, application and fundamental investigations. The present disclosure further relates the to the investigation of a BeO-based optically stimulated luminescence (OSL) dosimeter together with an OSL reader, and discusses the design and operation of an OSL reader, suitable to measure OSL emission of BeO-based dosimeters, for example beryllium oxide doped with sodium, dysprosium and erbium. The present disclosure further relates to the use of BeO-based compounds comprising BeO and at least one dopant selected from the group consisting of sodium, dysprosium and erbium as a fiber-coupled OSL dosimeter.

Abstract: A data processing device includes a chassis and at least one electronic component. The chassis includes a casing and a tray disposed in the casing. The tray includes a tray body and an operating member pivotally connected to the tray body. The tray body has an accommodating space. When the operating member is located at a closed position, the operating member and the casing are locked, and the at least one electronic component is able to be accommodated in the accommodating space. When the at least one electronic component is removed from the accommodating space, the operating member is able to rotate from the closed position to an opened position located in the accommodating space to be unlocked from the casing, so as to allow the tray to be removed from the casing.

Abstract: Examples of the present disclosure provide a terminal box for motor and a motor. 1. A terminal box for a motor, the terminal box comprising: a body defining space for a terminal block for connecting inner cables to outer cables; a first mounting structure on the body matching a second mounting structure on a housing of a motor, wherein the body is turnable around an axis within a set angle when mounted on the second mounting structure; and a first positioning structure on the body matching a second positioning structure on the housing, wherein the first positioning structure cooperates with the second positioning structure to lock the body against turning.

Abstract: A storage box includes a container portion and a lid portion. The container portion includes two lug parts and a gap defined therebetween. One side of each of the lug parts is formed with a lower elongated slit, and the lower elongated slits are coaxial with each other, and communicated with the gap. The lid portion includes a buckle piece bendably connected to one side of the lid portion, and two upper elongated slits are coaxial and opposite to each other. Each upper elongated slit is located between the upper main body and the buckle piece. When the lid portion covers the container portion, the buckle piece is bent into the gap, the upper elongated slits and the lower elongated slits are connected to each other, the buckle piece is abutted against the lug parts, and the lug parts are abutted against the buckle piece.

Abstract: Disclosed are a tricyclic fused heterocyclic compound having a PDE3/4 dual inhibitory effect represented by formula (I), a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating/preventing PDE3/4-mediated diseases. Each group in formula (I) is as defined in the description.

Abstract: Provided are a preparation method of a nanofiltration membrane with a tree-like structure and use. The preparation method includes: taking a cellulose fiber filter paper as a substrate, and allowing hydroxyapatite nanowire arrays to grow in situ through solvothermal synthesis to obtain a composite filter paper; and repeatedly soaking the composite filter paper in a solution of trimesic acid and iron chloride in ethanol to allow continuous deposition to obtain the nanofiltration membrane with the tree-like structure. The nanofiltration membrane with the tree-like structure of the present application has a larger surface roughness and a larger specific surface area than the conventional nanofiltration membranes, and thus exhibits a very high interception rate (higher than 94%) for anionic/cationic dyes and heavy metal ions Pb2+. Therefore, the nanofiltration membrane with the tree-like structure of the present application has excellent environmental benefits.

Abstract: Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, and eutectic or deuterated compound thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inhibitor in the preparation of a medication for treating related diseases. Each group in formula (I) is as defined in the description.

Abstract: Methods, apparatuses, and systems for determining a concentration of a target gas in a sample gas. An example method of preparing a replaceable testing material for detecting a target gas in a sample gas may include preparing a solution comprising a solute and a solvent, wherein the solute comprises o-tolidine; introducing a testing material substrate to the prepared solution for a period of time; and removing at least a portion of the solvent from the testing material substrate such that the testing material substrate comprises at least a portion of the o-tolidine, and thereby forming the replaceable testing material for detecting the target gas in the sample gas.

Abstract: An engaging mechanism includes a casing, a first engaging member and a second engaging member. The casing has a first engaging recess and a second engaging recess. The first engaging member is slidably disposed in the casing and has a first engaging portion. The second engaging member is rotatably disposed in the casing and has a second engaging portion. When the first engaging member is located at a first lock position, the second engaging member is able to rotate between a second lock position and a second unlock position. When the second engaging member is located at the second unlock position and the first engaging member slides from the first lock position to a first unlock position, the first engaging member pushes the second engaging member to rotate toward the second lock position, such that the second engaging portion blocks the second engaging recess.

Abstract: Provided are a sound effect display method and a terminal device. The method includes receiving a first operation input for a target audio file; and in response to the first operation, displaying a sound effect display interface corresponding to the target audio file, the sound effect display interface includes a foreground image and a background image, the foreground image includes a cover image corresponding to the target audio file, the background image is an image obtained by photographing a particle dot matrix at a preset photographic angle, the particle dot matrix includes a plurality of particle dots, initial positions of which are located on a first plane, and each particle dot of the particle dot matrix moves, according to a preset sound attribute of the target audio file, in the direction perpendicular to the first plane.

Abstract: Disclosed are a bicyclic peptide ligand having high affinity for Eph receptor tyrosine kinase A2 (EphA2), a drug conjugate containing the bicyclic peptide ligand and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same, and the use of the drug conjugate and the pharmaceutical composition in the preparation of a drug for preventing and/or treating EphA2 overexpressed disease.

Abstract: A compound of general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof, an intermediate thereof, and a use thereof in Bcl-2 family proteins-related diseases such as cancer.

Abstract: Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases.

Abstract: Disclosed are a compound as shown in formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, cocrystal or deuterated compound thereof, or a pharmaceutical composition containing same, and the use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases, wherein the definition of each group in formula (I) is as defined in the description.